Barahona Afonso Ana Filipa, João Cristina Maria Pires
Department of Chemistry, Universidade de Évora, Colégio Luís António Verney, Rua Romão Ramalho 59, 7000-671 Évora, Portugal.
Hematology Department, Champalimaud Center for the Unknown, Av. Brasília, 1400-038 Lisboa, Portugal.
Biomolecules. 2016 Mar 9;6(1):15. doi: 10.3390/biom6010015.
Immunoglobulin is a highly diverse autologous molecule able to influence immunity in different physiological and diseased situations. Its effect may be visible both in terms of development and function of B and T lymphocytes. Polyclonal immunoglobulin may be used as therapy in many diseases in different circumstances such as primary and secondary hypogammaglobulinemia, recurrent infections, polyneuropathies, cancer, after allogeneic transplantation in the presence of infections and/or GVHD. However, recent studies have broadened the possible uses of polyclonal immunoglobulin showing that it can stimulate certain sub-populations of T cells with effects on T cell proliferation, survival and function in situations of lymphopenia. These results present a novel and considerable impact of intravenous immunoglobulin (IVIg) treatment in situations of severe lymphopenia, a situation that can occur in cancer patients after chemo and radiotherapy treatments. In this review paper the established and experimental role of polyclonal immunoglobulin will be presented and discussed as well as the manufacturing processes involved in their production.
免疫球蛋白是一种高度多样化的自身分子,能够在不同的生理和疾病状态下影响免疫。其作用在B淋巴细胞和T淋巴细胞的发育及功能方面均可见。多克隆免疫球蛋白可在不同情况下用于多种疾病的治疗,如原发性和继发性低丙种球蛋白血症、反复感染、多发性神经病、癌症,以及在同种异体移植后出现感染和/或移植物抗宿主病的情况。然而,最近的研究拓宽了多克隆免疫球蛋白的可能用途,表明它可以刺激某些T细胞亚群,对淋巴细胞减少情况下的T细胞增殖、存活和功能产生影响。这些结果显示静脉注射免疫球蛋白(IVIg)治疗在严重淋巴细胞减少情况下具有新的显著影响,这种情况可能发生在癌症患者接受化疗和放疗后。在这篇综述文章中,将介绍和讨论多克隆免疫球蛋白已确立的和实验性的作用,以及其生产过程。